Tag - OSTX

Executive Moves

OS appoints Moderna co-founder Dr. Robert S. Langer as strategic advisor

OS Therapies (NYSE American: OSTX) has appointed Robert S. Langer, PhD, and co-founder of Moderna, to its strategic advisory board. According to OS, Dr. Langer will assist management with prioritizing the listeria...

April 13, 2026

Developments

OS to spin off OSAH into a standalone company

OS Therapies (NYSE American: OSTX) has announced its intent to spin off OS Animal Health (OSAH)—the company’s wholly owned subsidiary developing OST-HER2 for canine osteosarcoma—into a standalone public company...

November 20, 2025

Developments

USPTO grants OS NOA covering manufacturing of OST-HER2

OS Therapies (NYSE-A:OSTX) has announced that it has received a notice of allowance from the US Patent & Trademark Office (USPTO) covering the manufacturing methods required for OST-HER2. According to OS, the USPTO...

February 20, 2025

Developments

OS Phase 2b trial of immunotherapy candidate achieves primary endpoint with statistical significance

OS Therapies (NYSE-A:OSTX) has announced positive data from its Phase 2b clinical trial of OST-HER2, its targeted immunotherapy candidate, in the rare, pediatric-designated indication of preventing recurrent, fully...

January 15, 2025

Tag - OSTX

OS appoints Moderna co-founder Dr. Robert S. Langer as strategic advisor

OS to spin off OSAH into a standalone company

USPTO grants OS NOA covering manufacturing of OST-HER2

OS Phase 2b trial of immunotherapy candidate achieves primary endpoint with statistical significance

Subscribe